Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
INSULIN (HUMAN)
ELI LILLY (SINGAPORE) PTE LTD
A10AB01
100 iu/ml
INJECTION
INSULIN (HUMAN) 100 iu/ml
SUBCUTANEOUS, INTRAMUSCULAR
Pharmacy Only
Eli Lilly and Company (Primary Packager)
ACTIVE
1990-04-30
HUMULIN ® R (Regular human insulin [recombinant DNA origin], Lilly) HUMULIN ® N (NPH human insulin [recombinant DNA origin], Lilly) Isophane suspension HUMULIN ® L (Lente human insulin [recombinant DNA origin], Lilly) Zinc Suspension HUMULIN ® 30/70 30% Regular insulin human injection USP [recombinant DNA origin]) and (70% NPH insulin human isophane suspension [recombinant DNA origin] DESCRIPTION HUMULIN R: A sterile, clear colorless, aqueous solution of human insulin (DNA) adjusted to a pH of 7.0 to 7.8. Contains m-Cresol 0.25% added during manufacture as a preservative. HUMULIN N: A sterile suspension of a white, crystalline precipitate of isophane human insulin (DNA) in an isotonic phosphate buffer adjusted to a pH of 6.9 to 7.5. Contains m-Cresol 0.16% and phenol 0.065% added during manufacture as a preservative. HUMULIN L: A sterile suspension of 30% amorphous and 70% crystalline human insulin (DNA) zinc suspension, adjusted to a pH of 6.9 to 7.5. Contains methylparaben 0.1% added during manufacture as a preservative. HUMULIN 30/70: A sterile suspension of human insulin in the proportion of 30% soluble insulin and 70% isophane insulin. Contains m-Cresol 0.16% and phenol 0.065% added during manufacture as a preservative. All presentations are available in strengths of 100 units per ml. Not all presentations are available in the respective markets. INDICATIONS For the treatments of patients with diabetes mellitus for whom diet and/or oral agents are not sufficient. The use of human insulin (DNA) may be of particular benefit in the treatment of the following: insulin allergy, insulin-induced lipodystrophy, insulin Read the complete document
HUMULIN ® R (Regular human insulin [recombinant DNA origin], Lilly) HUMULIN ® N (NPH human insulin [recombinant DNA origin], Lilly) Isophane suspension HUMULIN ® L (Lente human insulin [recombinant DNA origin], Lilly) Zinc Suspension HUMULIN ® 30/70 30% Regular insulin human injection USP [recombinant DNA origin]) and (70% NPH insulin human isophane suspension [recombinant DNA origin] DESCRIPTION HUMULIN R: A sterile, clear colorless, aqueous solution of human insulin (DNA) adjusted to a pH of 7.0 to 7.8. Contains m-Cresol 0.25% added during manufacture as a preservative. HUMULIN N: A sterile suspension of a white, crystalline precipitate of isophane human insulin (DNA) in an isotonic phosphate buffer adjusted to a pH of 6.9 to 7.5. Contains m-Cresol 0.16% and phenol 0.065% added during manufacture as a preservative. HUMULIN L: A sterile suspension of 30% amorphous and 70% crystalline human insulin (DNA) zinc suspension, adjusted to a pH of 6.9 to 7.5. Contains methylparaben 0.1% added during manufacture as a preservative. HUMULIN 30/70: A sterile suspension of human insulin in the proportion of 30% soluble insulin and 70% isophane insulin. Contains m-Cresol 0.16% and phenol 0.065% added during manufacture as a preservative. All presentations are available in strengths of 100 units per ml. Not all presentations are available in the respective markets. INDICATIONS For the treatments of patients with diabetes mellitus for whom diet and/or oral agents are not sufficient. The use of human insulin (DNA) may be of particular benefit in the treatment of the following: insulin allergy, insulin-induced lipodystrophy, insulin resistance, and labile diabetes. HUMULIN R may also be of value during preparation of a diabetic patient for surgery or for hyperglycemic coma, trauma, or severe infection. DOSAGE AND ADMINISTRATION The dosage should be determined by the physician, according to the requirements of the patient. All HUMULIN preparations may be given by subcutaneous or intramuscular injection, but HUMULIN R may also Read the complete document